FDA Approves Barr's Application To Sell Generic Version Of Oral Contraceptive Yasmin

Main Category: Women's Health / Gynecology
Also Included In: Sexual Health / STDs;  Regulatory Affairs / Drug Approvals;  Pharma Industry / Biotech Industry
Article Date: 14 May 2008 - 7:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Barr Pharmaceuticals on Friday announced that FDA has approved its application to sell a generic version of Bayer Schering's oral contraceptive Yasmin in the U.S., Reuters reports (Reuters, 5/9).

In March, a federal court in New Jersey invalidated Bayer's patent on Yasmin, ruling in favor of a challenge filed by Barr (Daily Women's Health Policy Report, 3/5). Bayer has appealed the ruling to the U.S. District Court of Appeals for the Federal Circuit. Bayer also is suing Watson Pharmaceuticals and Sandoz over applications by the two companies to sell generic versions of Yasmin (AP/Forbes, 5/9).

Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women's Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women's Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company.

© 2008 The Advisory Board Company. All rights reserved.